Eli Lilly de Mexico, S.A. de C.V.

What Eli Lilly de Mexico, S.A. de C.V. does

Eli Lilly de Mexico, S.A. de C.V. is the Mexican operating subsidiary of Eli Lilly and Company (NYSE: LLY), the U.S. pharmaceutical corporation founded in 1876. Conducting business as "Eli Lilly México," the entity markets and distributes the parent's patented prescription medicines across six therapeutic areas: Alzheimer's disease, Cancer, Dermatology, Autoimmune conditions, Diabetes, and Obesity. The portfolio draws on more than 100 patented medicines developed over the parent's 150+ year manufacturing history, supported by 2 Nobel Prizes in Medicine awarded to affiliated researchers.

The business model is prescription-pharmaceutical distribution: the subsidiary sells patented medicines through healthcare providers, pharmacies, and medical facilities in Mexico, with no consumer-level direct-purchase channel disclosed. Pricing is not publicly itemized; pricing mechanics follow standard Mexican prescription-drug channels. Marketing combines patient education content (disease-specific webpages, video testimonials such as the obesity patient story featuring "Liz"), and a referral partnership with Top Doctors Latam that routes patients to qualified healthcare providers via tracked referral links. The primary customer segment is patients managing chronic and complex diseases, addressed through a hybrid segmentation approach that pairs consumer-facing education with provider-driven fulfillment.

Revenue, headcount, capital structure, and any Mexican-subsidiary-specific financials are not publicly disclosed. The entity operates exclusively within Mexico as a wholly-owned subsidiary of the publicly traded parent, with the parent providing portfolio, manufacturing expertise, and brand equity; the Mexican subsidiary provides local market presence, regulatory compliance, and a multi-channel patient/provider engagement layer. Manufacturing, anti-counterfeiting protections, and genetic-medicine research are repeatedly emphasized as differentiators, positioning the subsidiary as a patient-centered extension of the parent's global R&D and manufacturing platform.

Name

Eli Lilly de Mexico, S.A. de C.V.

Legal name

Eli Lilly de Mexico, S.A. de C.V.

Website

https://lilly.com.mx

Company type

Public

Founded year

2024

Operating status

Operating

Headcount range

11–50 employees

Short description

Eli Lilly de Mexico is the Mexican subsidiary of Eli Lilly and Company (NYSE: LLY) that markets and distributes the parent's 100+ patented prescription medicines across six therapeutic areas—Alzheimer's, Cancer, Dermatology, Autoimmune, Diabetes, and Obesity—to chronic-disease patients in Mexico via healthcare providers and pharmacies.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

akta.pro secondary industries

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF), Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)

Keywords

• Prescription pharmaceuticals
• Patented medications
• Chronic disease treatments
• Pharmaceutical manufacturing
• Biopharmaceutical products

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Marketing or Sales, Personnel

Distribution channels1 record

Marketing channels3 records

Core offering

Eli Lilly de Mexico develops, manufactures, and distributes patented prescription pharmaceutical medications across six therapeutic areas: Alzheimer's disease, Cancer, Dermatology, Autoimmune diseases, Diabetes, and Obesity. The Mexican subsidiary operates as part of Eli Lilly and Company's global pharmaceutical operations, providing patients with access to over 100 patented medicines developed through more than 150 years of manufacturing experience. The company also conducts genetic medicine research and invests in anti-counterfeiting measures to protect patient safety.

Product overview

Eli Lilly de Mexico is a pharmaceutical company that develops and manufactures patented medications. The company operates across six main therapeutic areas: Alzheimer's disease, Cancer, Dermatology, Autoimmune diseases, Diabetes, and Obesity. With over 150 years of experience manufacturing medications and more than 100 patented medicines, Eli Lilly focuses on creating life-changing medicines regardless of the prevalence or complexity of the disease. The company also emphasizes manufacturing quality, counterfeit product protection, and genetic medicine research.

Differentiator

Problem solved

Functional benefit

Products and services

• Pharmaceutical Medications

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Top Doctors LatamcoreChannel Partner/ Reseller/ DistributorEli Lilly Mexico partners with Top Doctors Latam to provide patients with access to healthcare providers. The partnership enables patients to search for medical attention and find qualified healthcare professionals for disease management. The partnership appears on Eli Lilly Mexico's website with referral links for patient consultations.

Scale indicators3 records

Recent moves4 records

Expansion highlights4 records

Broad incumbents

• Boehringer Ingelheim México: Boehringer Ingelheim's Mexican operations cover cardiometabolic and respiratory therapeutic areas, directly overlapping with Lilly's diabetes and obesity pillars; comparable as a peer multinational pharma affiliate targeting the same prescriber base in Mexico.
• Roche México: Roche's Mexican subsidiary markets branded pharmaceuticals across oncology and other specialty areas, overlapping directly with Eli Lilly's cancer and chronic-disease focus; comparable as a multinational pharma subsidiary operating in Mexico with a similar specialty/brand-driven model.
• Sanofi México: Sanofi's Mexican subsidiary operates a diversified branded pharmaceutical and specialty care portfolio including diabetes (insulin) and dermatology, directly overlapping with Eli Lilly Mexico's therapeutic areas and replicating the multinational-subsidiary model in the same Mexican market.
• Bayer México: Bayer's Mexican pharmaceutical division operates in women's health, cardiology, and specialty care, partially overlapping with Lilly's cardiometabolic focus; relevant as a multinational pharma affiliate with similar distribution-to-provider and patient-education orientation in Mexico.
• AstraZeneca México: AstraZeneca's Mexican affiliate markets innovative pharmaceuticals across oncology, cardiometabolic, and respiratory areas, overlapping with several of Lilly's therapeutic-area pillars; comparable as a multinational pharma subsidiary competing for the same healthcare-provider and patient-access channels in Mexico.
• Novartis México: Novartis's Mexican operations market branded innovative medicines, overlapping with Lilly's cardiometabolic and specialty areas; directly comparable as another global pharma multinational subsidiary distributing patented drugs through healthcare providers in Mexico.
• AbbVie México: AbbVie's Mexican operations span immunology and oncology, overlapping with Lilly's autoimmune and cancer franchises; directly comparable as a peer multinational pharmaceutical subsidiary bringing patented specialty medicines to the Mexican market.
• Merck Sharp & Dohme (MSD) México: MSD México markets branded pharmaceuticals across oncology and chronic disease categories; comparable as a peer multinational pharma subsidiary sharing Lilly's branded-innovator positioning, healthcare-provider channel, and patient-education approach in Mexico.
• Pfizer México: Pfizer's Mexican subsidiary operates as one of the largest multinational innovative pharmaceutical manufacturers in Mexico with a similarly broad therapeutic-area portfolio; directly comparable as a peer multinational pharma affiliate serving the same patient base and prescriber networks in Mexico.
• GSK México: GSK's Mexican subsidiary markets branded pharmaceuticals and vaccines including dermatology and specialty care franchises; relevant as a peer multinational pharma subsidiary distributing through healthcare providers in Mexico with overlapping chronic-disease and dermatology offerings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/eli-lilly-de-mexico-s.a.-de-c.v.

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eli Lilly de Mexico, S.A. de C.V.